Fig. 4: LC427 triggers antitumor immunity by inflaming tumor immune microenvironment.

A Schematic diagram showing the experimental design and timeline of MC38-Luc orthotopic model with vehicle (Ctrl) or 30 mg/kg LC427 treatment. B Representative bioluminescence images in MC38-Luc orthotopic mouse model with vehicle (Ctrl) or 30 mg/kg LC427 treatment at day 7, day 13, and day 19. C Tumor growth curve by the luminescence of MC38-Luc orthotopic tumor-bearing mice with Ctrl or 30 mg/kg LC427 treatment (n = 5 mice). D Representative tumor morphologies (left) and quantification of tumor sizes (right) from MC38-Luc orthotopic tumor-bearing mice with vehicle (Ctrl) or 30 mg/kg LC427 treatment (n = 5 mice). E Representative images (left) and quantification (right) of CD8 and CTLA4 IHC staining in tumor tissues from MC38-Luc orthotopic tumor-bearing mice with Ctrl or 30 mg/kg LC427 treatment (n = 5 mice). F, G Tumor volume and survival analysis of MC38 (F) and CT26 (G) tumor-bearing mice with vehicle (Ctrl), 30 mg/kg LC402 or 30 mg/kg LC427 treatment (n = 10 mice). H t-SNE plot showing 6,232 CD45⁺ immune cells of Ctrl-treated MC38 tumors or 7,633 CD45⁺ immune cells of LC427-treated MC38 tumors. I Quantification of various immune cell type infiltrations in H. J Quantification of intra-tumoral CD8⁺ T cells and CTLA4⁺ T cells in tumor tissues from MC38 (left) and CT26 (right) tumor-bearing mice by flow cytometry (n = 6 mice). K, L Representative images and quantification of CD8 and CTLA4 IHC staining in MC38 tumor tissues (K, n = 10 mice) and CT26 tumor tissues (L, n = 10 mice) from mice with Ctrl or 30 mg/kg LC427 treatment. Data are mean ± SEM. The n number represents biological replicates (individual mice) obtained from one independent experiment. Significance was assessed using two-way ANOVA, Kaplan-Meier survival analyses and unpaired two-tailed Student’s t-test. Source data are provided as a Source Data file.